NCT02900157View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 9, 2016

Primary Completion Date

January 23, 2020

Study Completion Date

January 23, 2020

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

MEDI9090

MEDI9090 will be administered by IV infusion

BIOLOGICAL

Durvalumab

Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.

Trial Locations (8)

28078

Research Site, Huntersville

78229

Research Site, San Antonio

80218

Research Site, Denver

85258

Research Site, Scottsdale

90025

Research Site, Los Angeles

135-8550

Research Site, Kōtoku

003-0804

Research Site, Sapporo

411-8777

Research Site, Sunto-gun

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT02900157 - Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter